Indication
Castration-Resistant Prostate Carcinoma
55 clinical trials
63 products
18 drugs
Product
XmAb20717Clinical trial
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-06-01
Clinical trial
A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2027-04-30
Product
ZEN-3694Product
EnzalutamideProduct
PembrolizumabClinical trial
Immunogenic Priming With PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer: A Phase 1b Study of 177Lu-PSMA-617 in Combination With PembrolizumabStatus: Active (not recruiting), Estimated PCD: 2024-01-10
Product
Lutetium Lu 177-PSMA-617Clinical trial
A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients With Metastatic Castration Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2019-10-16
Product
CabazitaxelClinical trial
Phase IB/II Study of Enzalutamide With Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB ExpressionStatus: Completed, Estimated PCD: 2022-12-06
Product
RibociclibClinical trial
Re-Treatment With 177Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer: A Prospective Phase 2 Trial (RE-LuPSMA STUDY)Status: Not yet recruiting, Estimated PCD: 2026-01-27
Clinical trial
Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPCStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Phase II Trial of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (HP) Plus Enzalutamide for the Treatment of Selected Patients With Metastatic Castration-Resistant Prostate Cancer (TraPPer)Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)Status: Recruiting, Estimated PCD: 2025-01-31
Product
AvelumabProduct
PeposertibClinical trial
A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2023-03-14
Product
CediranibProduct
OlaparibDrug
R-CHOPClinical trial
A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
BerzosertibProduct
CarboplatinDrug
DocetaxelClinical trial
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage ResponseStatus: Recruiting, Estimated PCD: 2024-12-01
Product
TalazoparibClinical trial
A Pilot Trial to Explore the Link Between Immunological Changes, Efficacy, Safety, and Tolerability of Durvalumab (MEDI4736) Plus Tremelimumab in Chemotherapy-Naïve Men With Metastatic Castration-Resistant Prostate Cancer (CRPC)Status: Completed, Estimated PCD: 2021-04-13
Product
DurvalumabProduct
TremelimumabClinical trial
Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide TreatmentStatus: Active (not recruiting), Estimated PCD: 2019-10-01
Clinical trial
Efficacy of Ra-223 in PSMA PET Optimally Selected PatientsStatus: Not yet recruiting, Estimated PCD: 2026-01-31
Drug
Radium-223Product
Technetium Tc 99M MedronateClinical trial
Olaparib in Prostate Cancer Patients With Evidence of Homologous Recombination Deficiency as Assessed Using an Integrated Genomic SignatureStatus: Terminated, Estimated PCD: 2023-10-15
Clinical trial
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-05-15
Product
RucaparibProduct
PlaceboDrug
LHRH agonistProduct
GoserelinProduct
DegarelixClinical trial
A Phase 2, Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Metastatic Prostate Cancer Patients Evaluating a Predetermined Biomarker SignatureStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Product
ApalutamideClinical trial
A Randomized, Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on PSMA-PET ImagingStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
Phase 2 Study of CJNJ-67652000 (Niraparib/Abiraterone Acetate Fixed-Dose Combination) and Prednisone for Metastatic Castration-Resistant Prostate Cancer Associated With SPOP Mutation With or Without Homologous Recombination DeficiencyStatus: Recruiting, Estimated PCD: 2024-09-01
Product
PrednisoneClinical trial
Minority-Inclusive Imaging Biomarker-Based End of Therapy Trial for 177Lu-PSMA-617, a Randomized De-Escalation Theranostic Trial for Metastatic Castrate Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2029-12-31
Clinical trial
A Phase 2 Study of 68Ga-PSMA-11 PET in Patients With Metastatic Castration Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2023-09-30
Drug
68Ga-PSMA-11Clinical trial
Phase 1/2 Dose-Escalation and Cohort Study of STEAP1 CART With Enzalutamide in Participants With mCRPCStatus: Not yet recruiting, Estimated PCD: 2027-03-30
Product
Anti-STEAP1 CAR T-cellsDrug
cyclophosphamideDrug
fludarabineClinical trial
Immune Activation and Cellular Response From Enzalutamide Alone or With Radium223 in Men With Metastatic, Castration-Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-11-21
Clinical trial
Vorinostat to Augment Response to Lutetium-PSMA-617 in the Treatment of Patients With PSMA-Low Metastatic Castration-Resistant Prostate CancerStatus: Not yet recruiting, Estimated PCD: 2025-12-30
Product
VorinostatClinical trial
68Ga-PSMA-11 PET/CT for Screening Prior to 177Lu-PSMA-617 TherapyStatus: Completed, Estimated PCD: 2023-12-31
Product
GozetotideClinical trial
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV InfectionStatus: Active (not recruiting), Estimated PCD: 2025-11-02
Product
CabozantinibClinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIMEStatus: Terminated, Estimated PCD: 2020-12-10
Product
AbemaciclibProduct
AbirateroneProduct
AfatinibDrug
T-VECDrug
AtezolizumabClinical trial
PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair DeficiencyStatus: Active (not recruiting), Estimated PCD: 2025-05-15
Drug
AN0025Product
BicalutamideProduct
BortezomibClinical trial
A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to DocetaxelStatus: Active (not recruiting), Estimated PCD: 2022-07-25
Product
AZD8186Product
DabrafenibProduct
DacomitinibClinical trial
Phase Ib/II Study of Enzalutamide With Venetoclax (ABT-199) in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)Status: Completed, Estimated PCD: 2022-07-18
Product
VenetoclaxDrug
UTD1Clinical trial
TRAMP: Tumor Necrosis Factor- α Blockade and AR Inhibition in Men With CRPCStatus: Recruiting, Estimated PCD: 2027-03-31
Product
GolimumabDrug
CelecoxibClinical trial
An Open-Label, Parallel, Phase II Study of Single-Agent Oral ESK981 in Men With Castrate-Resistant Prostate Cancer (CRPC)Status: Completed, Estimated PCD: 2023-03-15
Product
ESK981Product
DasatinibProduct
CobimetinibProduct
DarolutamideProduct
CopanlisibClinical trial
AtezoCab: A Phase II Study of Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Non-Measurable DiseaseStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Bipolar Androgen Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Status: Recruiting, Estimated PCD: 2026-04-01
Product
Testosterone CypionateProduct
EnasidenibClinical trial
A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Drug
EntrectinibProduct
IpilimumabDrug
ErlotinibClinical trial
Bipolar Androgen Therapy Plus Olaparib in Patient With Castration-Resistant Prostate CancerStatus: Completed, Estimated PCD: 2021-03-05
Product
Testosterone EnanthateClinical trial
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)Status: , Estimated PCD: 2024-11-30
Clinical trial
Phase I/II Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Product
IvuxolimabProduct
UtomilumabClinical trial
Erdafitinib Plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate CancerStatus: Terminated, Estimated PCD: 2021-06-06
Product
ErdafitinibClinical trial
A Phase 1b Clinical Trial: Improving Outcomes With Androgen Pathway Inhibitors by Targeting DNA Methyltransferase ActivityStatus: Recruiting, Estimated PCD: 2025-01-30
Product
Decitabine and CedazuridineClinical trial
A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination With Olaparib in Patients With BRCA1/2-Mutant TumorsStatus: Withdrawn, Estimated PCD: 2026-12-06
Product
MagrolimabClinical trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 TrialStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Product
Antiandrogen TherapyClinical trial
SPECTRA: SupraPhysiological Androgen to Enhance Chemotherapy TReatment ActivityStatus: Recruiting, Estimated PCD: 2027-03-31
Product
EtoposideClinical trial
A First-in-Human, Phase I PET Imaging Study of 11C-YJH08, a Selective Glucocorticoid Receptor-Targeting Agent, in Patients With Advanced Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2025-10-31
Product
11C-YJH08Clinical trial
68Ga-PSMA-11 PET in Patients With Prostate CancerStatus: Recruiting, Estimated PCD: 2024-09-30
Product
Gallium Ga 68 GozetotideClinical trial
Molecular Imaging With Ga-68 DOTATATE PET to Investigate Neuroendocrine Differentiation in Prostate Cancer PatientsStatus: Completed, Estimated PCD: 2023-02-06
Product
Gallium Ga 68-DOTATATEClinical trial
Phase I/II Study of CDK4/6 Inhibition With Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and ChemotherapyStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase II Trial of Immune Checkpoint Inhibitor With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate CancerStatus: Completed, Estimated PCD: 2021-01-20
Product
HER2BiDrug
mFOLFOX6Clinical trial
The Impact of DNA Repair Pathway Alterations Identified by Circulating Tumor DNA on Sensitivity to Radium-223 in Bone Metastatic Castration-Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2024-08-01
Product
Radium Ra 223 DichlorideClinical trial
A Study of Erdafitinib in Castration-Resistant Prostate Cancer Patients Evaluating Markers of Bone Remodeling and FGF Signaling in Plasma and Bone MarrowStatus: Active (not recruiting), Estimated PCD: 2026-06-30
Clinical trial
A Phase 1b Study Evaluating Combinations With PSCA-Targeting Chimeric Antigen Receptor (CAR)-T Cells for Patients With PSCA+ Metastatic Castration-Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (UC), and Renal Cell (RCC) CarcinomasStatus: Recruiting, Estimated PCD: 2026-12-31
Drug
LurbinectedinDrug
ValemetostatClinical trial
Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate CancersStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Product
CetrelimabClinical trial
A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant SignatureStatus: Not yet recruiting, Estimated PCD: 2027-06-30